Article Information
History
- July 5, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Yuta Asano1,*,
- Joshua Veatch1,2,*,
- Megan McAfee1,
- Jakob Bakhtiari1,
- Bo Lee1,
- Lauren Martin1,
- Shihong Zhang1,
- Francesco Mazziotta1,
- Kelly G. Paulson3,
- Thomas M. Schmitt1,
- Ariunnaa Munkbhat1,
- Cecilia Young1,
- Brandon Seaton1,
- Daniel Hunter1,
- Nick Horst1,
- Marcus Lindberg1,
- Natalie Miller1,
- Matt Stone1,
- Jason Bielas1,2,
- David Koelle1,2,4,
- Valentin Voillet1,
- Raphael Gottardo1,2,
- Ted Gooley1,
- Shannon Oda5,
- Philip D. Greenberg1,2,
- Paul Nghiem1,2 and
- Aude G. Chapuis1,2,#
- 1Fred Hutchinson Cancer Center, Seattle, WA, USA
- 2University of Washington, Seattle, WA, USA
- 3Swedish Health Services, Edmonds, WA, USA
- 4Benaroya Research Institute, Seattle, WA, USA
- 5Seattle Children’s Research Institute, Seattle, WA, USA
- ↵#Corresponding Author: Aude G. Chapuis, MD, Fred Hutchinson Cancer Center 1100 Fairview Ave N, Seattle, WA 98109, achapuis{at}fredhutch.org, 206-667-4369 (phone), 206-667-7983 (fax)
↵* These authors contributed equally.
Posted July 05, 2024.
Tumor Regression Following Engineered Polyomavirus-Specific T Cell Therapy in Immune Checkpoint Inhibitor-Refractory Merkel Cell Carcinoma
